00:43 , Jan 30, 2019 |  BC Extra  |  Company News

Allergan sheds $4.5B in market cap on 4Q18 earnings

Allergan plc (NYSE:AGN) lost $13.57 to $145.12 on Tuesday after it reported a $4.3 billion net loss in 4Q18 and presented 1Q19 guidance well below the Street’s consensus. The stock move translates to a loss...
19:01 , Jan 18, 2019 |  BC Week In Review  |  Financial News

Mirati, Revance price follow-ons

Mirati Therapeutics Inc. (NASDAQ:MRTX) and Revance Therapeutics Inc. (NASDAQ:RVNC) have each raised $100 million in follow-ons. Mirati priced 1.6 million shares at $62 late on Jan. 16. The price is a slim discount to the...
21:45 , Jan 17, 2019 |  BC Extra  |  Financial News

Mirati, Revance price follow-ons

Mirati Therapeutics Inc. (NASDAQ:MRTX) and Revance Therapeutics Inc. (NASDAQ:RVNC) have each raised $100 million in follow-ons. Mirati priced 1.6 million shares at $62 late Wednesday. The price is a slim discount to the company’s close...
16:37 , Sep 21, 2018 |  BC Week In Review  |  Company News

Allergan to acquire botulinum neurotoxin play Bonti

Allergan plc (NYSE:AGN) will acquire Bonti Inc. (Newport Beach, Calif.) for $195 million up front. Bonti shareholders are also eligible for undisclosed commercial milestone payments. Allergan and Bonti declined to disclose details. In May, Allergan...
06:10 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Bonti's EB-001A improves scar appearance following Mohs surgery in Phase IIa

Bonti Inc. (Newport Beach, Calif.) said EB-001A improved scar appearance by about 50% vs. placebo as measured by investigator-assessed visual analog scale (VAS) scores at day 30 in the Phase IIa SHINE-1 trial in 12...
20:40 , Jun 14, 2018 |  BC Week In Review  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the double-blind, U.S. Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the...
21:23 , Jun 11, 2018 |  BC Extra  |  Clinical News

Allergan's atogepant meets in Phase IIb/III to prevent migraine

Allergan plc (NYSE:AGN) said all doses of oral atogepant (MK-8031) met the primary endpoint in the Phase IIb/III CGP-MD-01 trial to prevent episodic migraine. The company declined to disclose next steps for the small molecule...
19:42 , May 18, 2018 |  BC Week In Review  |  Clinical News

FDA approves Aimovig as first CGRP inhibitor for migraines

FDA approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) late on May 17 to prevent migraine in adults. The drug is the first calcitonin gene-related peptide (CGRP) inhibitor approved for the...
04:05 , May 18, 2018 |  BC Extra  |  Company News

FDA approves Aimovig as first CGRP inhibitor for migraines

FDA approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) late Thursday to prevent migraine in adults. The drug is the first calcitonin gene-related peptide (CGRP) inhibitor approved for the indication. Amgen...
02:31 , May 18, 2018 |  BC Week In Review  |  Clinical News

FDA frowns on Evolus

Evolus Inc. (NASDAQ:EOLS) said FDA issued a complete response letter for a BLA for prabotulinumtoxinA (DWP-450) to treat adults with glabellar lines (frown lines between the eyebrows). Evolus shed over $90 million in market cap...